Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
about
Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo.Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.Treating KRAS-mutant NSCLC: latest evidence and clinical consequences.Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.
P2860
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
@ast
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
@en
type
label
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
@ast
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
@en
prefLabel
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
@ast
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
@en
P2093
P2860
P50
P356
P1433
P1476
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
@en
P2093
Anna Ronchi
Daniela Salles
Giuseppe Rotella
Lisa Wiesmüller
Nikola Mattschas
Stefano Colavecchio
P2860
P304
30072-30087
P356
10.18632/ONCOTARGET.5019
P407
P577
2015-10-01T00:00:00Z